BIO.B Valuation

Bio Rad Laboratories Inc

Add to Watchlist

Advanced Chart

258.170

+11.12(4.501%)1D

Overview
Forecast
Valuation
Earnings

BIO.B Relative Valuation

BIO.B's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIO.B is overvalued; if below, it's undervalued.

Historical Valuation

Bio Rad Laboratories Inc (BIO.B) is now in the Fair zone, suggesting that its current forward PE ratio of 28.58 is considered Fairly compared with the five-year average of 28.69. The fair price of Bio Rad Laboratories Inc (BIO.B) is between 239.20 to 273.44 according to relative valuation methord.

Relative Value

Fair Zone

239.20-273.44

Current Price：258.17

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.03

P/B

Median3y

1.18

Median5y

1.18

5.34

FCF Yield

Median3y

3.35

Median5y

3.35

Competitors Valuation Multiple

The average P/S ratio for BIO.B's competitors is 5.14, providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO.B) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -4.16%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BIO.B.N

Bio Rad Laboratories Inc

Loss

Average P/S: 5.14

-4.16%